A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials-Reference-Cited by-同舟云学术

A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials

Published:2016-10-31 Issue:2 Volume:31 Page:318-324
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Montalban-Bravo G,Huang X,Jabbour E,Borthakur G,DiNardo C D,Pemmaraju N,Cortes J,Verstovsek S,Kadia T,Daver N,Wierda W,Alvarado Y,Konopleva M,Ravandi F,Estrov Z,Jain N,Alfonso A,Brandt M,Sneed T,Chen H-C,Yang H,Bueso-Ramos C,Pierce S,Estey E,Bohannan Z,Kantarjian H M,Garcia-Manero G

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

https://www.nature.com/articles/leu2016303.pdf

Reference34 articles.

1. Yao B, Zhu L, Jiang Q, Xia HA . Safety monitoring in clinical trials. Pharmaceutics 2013; 5: 94–106.

2. Yanada M, Okamoto A, Inaguma Y, Tokuda M, Morishima S, Kanie T et al. The fate of patients with acute myeloid leukemia not undergoing induction chemotherapy. Int J Hematol 2015; 102: 35–40.

3. Bell JA, Balneaves LG . Cancer patient decision making related to clinical trial participation: an integrative review with implications for patients’ relational autonomy. Support Care Cancer 2015; 23: 1169–1196.

4. Mengis C, Aebi S, Tobler A, Dahler W, Fey MF . Assessment of differences in patient populations selected for excluded from participation in clinical phase III acute myelogenous leukemia trials. J Clin Oncol 2003; 21: 3933–3939.

5. Kantarjian H, O’Brien S, Cortes J, Giles F, Faderl S, Jabbour E et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer 2006; 106: 1090–1098.

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Beyond the horizon: emerging therapeutic approaches in myelodysplastic neoplasms;Experimental Hematology;2024-02

2. Assessment of 2022 European LeukemiaNet risk classification system in real‐world cohort from China;Cancer Medicine;2023-12

3. HDAC inhibitors: Promising agents for leukemia treatment;Biochemical and Biophysical Research Communications;2023-11

4. Use, variability, and justification of eligibility criteria for phase II and III clinical trials in acute leukemia;Haematologica;2023-08-10

5. Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine;Blood Cancer Journal;2023-06-19